The Vice Chancellor, David Umahi, Federal University of Health Sciences, Uburu, Prof Josse Uneke, on Thursday said that an estimated 24 million Nigerians have sight loss due to health implications, ...
Faricimab demonstrated noninferior vision gains and improved anatomical outcomes among patients with diabetic macular edema ...
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...
Artificial blue light from devices and screens is not kind on your eyes or your overall health. Here are the best blue light ...
The Sing IMT improved distance and near vision at 6 months in patients with late-stage age-related macular degeneration, with ...
The US Food and Drug Administration (FDA) approved expanding the prescribing information for Japanese drugmaker Astellas ...
Sight Care is formulated in a GMP-certified and FDA-registered facility in the United States, ensuring each batch meets ...
H.C. Wainwright analyst raised the price target on Ocugen, Inc. (NASDAQ:OCGN) to $8.00, up from the previous $7.00, while maintaining a Buy rating on the stock. Currently trading at $0.66, the stock ...
Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...
PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...
Hosted on MSN15h
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved!Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback